P95 Julius Clinical recently submitted the first regimen-specific protocol to the U.S. Food and Drug Administration (FDA) for The Michael J. Fox Foundation’s Path to Prevention (P2P) platform trial. Click here to read the full announcement. The submission is a milestone in Parkinson’s research, but it also reflects a broader change in how clinical development is done. Across therapeutic areas, from neurodegeneration to emerging infectious diseases, the conditions we most need to address increasingly strain the limits of the traditional randomized controlled trial. In response, sponsors and regulators are turning to modern evidence strategies, including adaptive and platform trial designs, external control arms, biomarker-based enrichment, and real-world evidence, to generate credible evidence of benefit by other means. This article examines that shift and what it means for sponsors developing therapies for complex diseases.
The limits of the traditional randomized controlled trial
The randomized controlled trial (RCT) remains the gold standard for evaluating efficacy and safety, and in some situations, it is also the fastest route to authorization. In others, its resource-intensive and time-consuming nature can make it impractical, prohibitively expensive, or too slow, and it may not capture the full range of real-world patients who will ultimately receive a therapy. These constraints are prompting a re-examination, across disciplines, of how credible efficacy evidence can be generated when a conventional large-scale trial is not feasible. Two current examples, one in neuroscience and one in vaccines, illustrate how that question is being answered in practice.
Adaptive and platform designs: the Parkinson’s example
One response is to change the architecture of the trial itself. A platform trial evaluates multiple investigational therapies under a single master protocol, adding new treatment arms as evidence emerges and discontinuing those that do not perform. The FDA has noted that well-designed master protocols can improve efficiency, reduce the number of participants needed for control groups, and lessen patient burden. The P2P trial applies this approach to Parkinson’s disease (PD). It is built upon the Parkinson’s Precision Medicine Initiative (PPMI), a longitudinal study that has collected clinical and biomarker data for more than 15 years, enabling identification of individuals who carry biological markers of Parkinson’s before symptoms appear and supporting external and shared control arms that reduce the number of participants assigned to placebo. With Parkinson’s now the fastest-growing neurological disorder worldwide and no approved therapy that slows its progression, an efficient, continuously learning design is well matched to the scale of the problem.
Learn more about P95 Julius Clinical’s neuroscience CRO capabilities and experience in neuroscience here.
Real-world evidence and the licensing of vaccines
A parallel shift is underway in infectious diseases and vaccines, where clinical-endpoint efficacy trials are sometimes impractical, for example when disease incidence is low or an outbreak moves faster than a trial can be mounted. In a recent international meeting report, P95 Julius Clinical’s Laurence de Moerlooze, Head of Infectious Diseases and Vaccines, and Kaatje Bollaerts, Head of Real-World Evidence, together with an expert working group, examined how vaccines can be evaluated and licensed when a traditional phase III efficacy trial is not feasible. The approaches they reviewed, including controlled human infection models, correlates of protection, pragmatic trials, and the use of real-world evidence to confirm benefit after approval, share a common logic with adaptive trial designs: each generates credible evidence of efficacy through a route other than a single, large, conventional RCT.
Read the full peer-reviewed publication, Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence – a meeting report, here.
Implications for sponsors of complex therapeutic programs
For sponsors, the practical implication is that evidence strategy is now a design decision rather than an afterthought. The relevant question is no longer whether to incorporate real-world evidence and adaptive approaches, but how early and how rigorously to build them into a development plan. P95 Julius Clinical combines complex trial operations across neuroscience and infectious diseases with real-world evidence capabilities that span therapeutic areas, allowing sponsors to move from an individual protocol toward a coherent evidence strategy designed to meet regulatory requirements, inform payer decisions, and shorten the path to therapies that prevent or modify disease.
The P2P submission and the ongoing re-examination of vaccine licensure are two expressions of the same shift: as the science grows more complex, the methods used to prove that a therapy works are evolving with it. Read the full announcement on the P95 Julius Clinical newsroom.
0 Comments